Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Podcasts|September 10, 2024
Drug Solutions Podcast: Meeting Industry Needs: Fill/Finish Advances from a CDMO Perspective
Author(s)Felicity Thomas
In this sponsored episode, Jörg Zimmermann from Vetter chats about fill/finish advances.
Advertisement
In this sponsored podcast, Felicity Thomas, Associate Editorial Director, chats with Jörg Zimmermann, Vice President, Vetter Development Service, about fill/finish advances. Topics covered in the discussion include the current state of Annex 1 within industry, drivers impacting the growth of the CDMO market, best practices for partner selection, ways in which partner companies ensure balance between demand and quality, Vetter’s practices to meet demand, and the trends defining fill/finish from the perspective of a CDMO.
Sponsor
About the Speaker
Jörg Zimmermann, Vice President, Vetter Development Service
About the Drug Solutions Podcast
Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.
Listen to this podcast on
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement